1h Free Analyst Time
Global Opioid-Induced Constipation Market 2020-2024Speak directly to the analyst to clarify any post sales queries you may have.
The opioid-induced constipation market is poised to grow by $ 3.39 bn during 2020-2024, progressing at a CAGR of 21% during the forecast period. The reports on the opioid-induced constipation market provide a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increase in opioid prescriptions globally, a rise in the geriatric population, and the availability of reimbursements for opioid-based medications. In addition, an increase in opioid prescriptions globally is anticipated to boost the growth of the market as well.
The opioid-induced constipation market analysis includes the route of administration segment, class of drug, and geographical landscapes.
The opioid-induced constipation market is segmented as below:
By Route of Administration
- Oral
- Parenteral
By Class of Drugs
- Peripherally acting mu-opioid receptor antagonists
- Locally acting chloride channel activator
- Others
By Geographical Landscapes
- North America
- Europe
- Asia
- ROW
This study identifies the rise in the incidence of chronic diseases such as arthritis, back pain, and migraine as one of the prime reasons driving the opioid-induced constipation market growth during the next few years. Also, market dominance by opioid receptor antagonists and the introduction of separate diagnostic guidelines for idiopathic or functional constipation and opioid-induced constipation will lead to sizable demand in the market.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
The report on the opioid-induced constipation market covers the following areas:
- Opioid-induced constipation market sizing
- Opioid-induced constipation market forecast
- Opioid-induced constipation market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading opioid-induced constipation market vendors that include AstraZeneca Plc, Bausch Health Companies Inc., Daiichi Sankyo Co. Ltd., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., SHIONOGI Co. Ltd., and Takeda Pharmaceutical Co. Ltd. Also, the opioid-induced constipation market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.
This market research report provides a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Table of Contents
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Route of Administration
Market Segmentation by Class of Drugs
Customer Landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global opioid-induced constipation market: AstraZeneca Plc, Bausch Health Companies Inc., Daiichi Sankyo Co. Ltd., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., SHIONOGI Co. Ltd., and Takeda Pharmaceutical Co. Ltd.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is the rise in incidence of chronic diseases such as arthritis, back pain, and migraine."
According to the report, one of the major drivers for this market is the increase in opioid prescriptions globally.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca Plc
- Bausch Health Companies Inc.
- Daiichi Sankyo Co. Ltd.
- Ironwood Pharmaceuticals Inc.
- Mallinckrodt Plc
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- SHIONOGI Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
